| Type | Public |
|---|---|
| Headquarters |  Novato,
CA, USA |
| Key people | Jean-Jacques Bienaime |
| Industry | Biotechnology |
| Employees | 525[1] |
| Website | www.biomarinpharm.com |
BioMarin Pharmaceutical (NASDAQ: BMRN) is a biotechnology firm based in Novato, California. It has offices and facilities in the US, South America, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin is the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing Aldurazyme (commercialized by Genzyme Corporation). BioMarin is also the first company to provide therapeutics for Phenylketonuria (PKU)
As of 2005, BioMarin commercialized arylsulfatase B (Naglazyme) as an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), and in 2007 a drug version of tetrahydrobiopterin (Kuvan), the first medication-based intervention to treat phenylketonuria.[2]
  | Company Profile for BioMarin Pharmaceutical Inc (BMRN) - Quote Search - Fundamental Data, Company Proflem, and more... |
| | Agency Approves Drug to Treat Genetic Disorder That Can Lead to Retardation - The New York Times > Log In |
|
|
Wikis
Map
Search